BC Innovations | Nov 19, 2019
Distillery Therapeutics

Combining Arava with HIF1A inhibition to treat RA

DISEASE CATEGORY: Autoimmune disease INDICATION: Rheumatoid arthritis (RA) Inhibiting HIF1A could enhance the efficacy of Arava leflunomide for RA-associated bone erosion in patients with high C-reactive protein levels. In a rat model of RA, Arava...
BC Extra | Oct 8, 2019
Tools & Techniques

Nobel Prize for cell response to oxygen, a two-sided therapeutic target

Cellular responses to oxygen levels, the focus of this year's Nobel Prize in Physiology or Medicine, are the targets of both inhibiting and activating therapies in clinical development for multiple diseases. William Kaelin, Peter Ratcliffe...
BC Week In Review | Feb 13, 2019
Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Feb. 7 . Gossamer was up $1.94 (12%) to $17.94 on its first day of trading Feb. 8. Launched officially just 13 months...
BC Extra | Feb 8, 2019
Financial News

Gossamer Bio prices $276M IPO

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Thursday. Trading is to begin Friday. Launched officially just 13 months ago by ex-Receptos Inc. executives, Gossamer is developing therapeutics for inflammation,...
BC Extra | Dec 22, 2018
Financial News

Gossamer Bio seeks $264.5 million IPO one year after launch

Gossamer Bio Inc. (San Diego, Calif.) plans to raise up to $264.5 million in an IPO on NASDAQ, according to a Dec. 21 SEC filing. The company was launched by ex-Receptos Inc. executives in January...
BC Innovations | Dec 4, 2018
Distillery Therapeutics

Infectious disease

INDICATION: Clostridium Patient sample, cell culture and mouse studies suggest inhibiting VEGF-A, VEGFR-2 or HIF1 could help treat Clostridium difficile infection (CDI). In serum samples from patients, levels of VEGF-A were higher than in samples...
BC Week In Review | Jul 27, 2018
Financial News

With Ex-Receptos execs at helm, Gossamer raises another large round

Gossamer Bio Inc. (San Diego, Calif.) raised $230 million on July 23 in an untranched series B round led by new investor Hillhouse Capital, bringing the biotech's total funding to $330 million since its January...
BioCentury | Jul 26, 2018
Finance

Gossamer’s war chest

Gossamer Bio Inc. has built a huge war chest from investors lured by the prospect of near-term milestones, a plan for rapid pipeline growth and a winning management team from Receptos Inc. With Monday’s $230...
BC Extra | Jul 23, 2018
Financial News

Ex-Receptos team snags another big round at Gossamer

Gossamer Bio Inc. (San Diego, Calif.) raised $230 million in an untranched series B round led by new investor Hillhouse Capital, bringing the biotech's total funding to $330 million since its January launch. Also participating...
Other News | Apr 20, 2018
Other News

Broad launches tool to identify vulnerabilities of cancer cells

The Broad Institute of MIT and Harvard University launched a publicly available online portal that allows any researcher worldwide to access and analyze data on genetic and pharmacologic dependencies of cancer cell lines, and associated...
Items per page:
1 - 10 of 99